Keywords :
Airway inflammation; Asthma; Decline; Eosinophils; Lung Diseases; Interleukin-8; CXCL8 protein, human; Biomarkers; Immunoglobulin E; Interleukin-5; Humans; Male; Female; Middle Aged; Forced Expiratory Volume; Adult; Leukocyte Count; Time Factors; Disease Progression; Lung/physiopathology; Immunoglobulin E/blood; Interleukin-5/blood; Sputum/immunology; Asthma/physiopathology; Asthma/blood; Asthma/immunology; Asthma/diagnosis; Interleukin-8/blood; Biomarkers/blood
Abstract :
[en] [en] BACKGROUND: Asthma is associated with accelerated rate of FEV1 decline.
OBJECTIVE: To determine predictive factors associated with accelerated FEV1 decline in adult asthma and evaluate sputum cytokines as potential biomarkers for airflow decline.
METHODS: We recruited 125 asthmatics evaluated at the asthma clinic of Liège and reevaluated them at least 5 years later. Clinical, functional and inflammatory characteristics were compared between patients with accelerated decline (FEV1 decline > 0.85% pred.y-1) and others. Predictive factors were highlighted with linear regression analysis. Sputum EGF, VEGF, FGF, IL5, IL8, TGF-β, and IgE levels were measured in 58 of these patients at both visits by Human XL cytokine Luminex Performance assay and Elisa.
RESULTS: Post-BD FEV1 decline was 0.06 ± 2.44% pred.y-1 in the overall population. Median (IQR) time between visits was 66 (62 - 86) months. The multivariable analysis showed that an increase in blood eosinophils over time (Δ BEC) (Reg. Coef. (95%CI): 0.002 (0.001 to 0.004), p = 0.005)) and onset of asthma (0.04 (0.003 to 0.07), p = 0.036) were independently associated with FEV1 decline. IL8 levels measured at baseline were higher (499 (408-603) pg/ml, p = 0.0040) in patients with accelerated decline compared to others (143 (88-308) pg/ml).
CONCLUSION: In this study, we have confirmed that an increase in blood eosinophil counts over a follow-up of at least 5 years and later onset of asthma are associated with accelerated annual FEV1 decline. Moreover, high sputum IL8 levels could be a risk factor for accelerated decline in asthma patients.
Scopus citations®
without self-citations
0